Refugee Enhanced Vaccination Program






Division of Global Migration and Quarantine NVAC Meeting February 2016




FY 2015 U.S. Refugee Arrivals Top 10 by Nationality



- Does not include paroles and asylum seekers who arrive by sea or across ta land border.
- Data source: Disease Notification Analysis (DNA) database based on Worldwide Refugee Admissions Processing System (WRAPS) from the U.S. Department of State




FY 2015 U.S. Refugee Arrivals Top 10 by Nationality, total arrivals = 69,933







FY 2006 – 2015 U.S. Refugee Arrivals, by Nationality







U.S. Refugee Admissions, FY 2016 Program*

Region	Ceiling for FY 2016	Primary populations	
Africa	25,000	Congolese in Rwanda, Tanzania, Uganda, Burundi; Somalis in Kenya, Ethiopia, Uganda; Eritreans in Sudan and Ethiopia	
East Asia	13,000	Burmese in Thailand and Malaysia	
Europe/ Central Asia	4,000	Religious minorities from the former Soviet Union	
Latin America	3,000	Cubans (many) and Colombians (few), Central American minors	
N. East/S. Asia	34,000	Bhutanese in Nepal, Iraqis, Iranian religious minorities, Syrians	
Unallocated Reserve	6,000	Available as needed for any region	
Total	85,000		

Migration Health



FY 2015 U.S. Refugee Arrivals by State







Vaccination of U.S.-Bound Refugees

- 70,000 85,000 refugees resettled (>70 nationalities from 100 countries) to 49 states annually
- Refugees not legally required to get vaccinations before U.S. resettlement
 - Many refugees arrive in U.S. with no documented vaccinations
- > 40 vaccine-preventable disease outbreaks in last 5 years
- Missed opportunity to vaccinate refugees between required overseas health assessment & arrival in U.S. (4-6 months)





Selected Vaccine Preventable Diseases Affecting U.S.-bound Refugees

2003-2005: Measles, rubella, varicella, Côte D'Ivoire (Liberian refugees)

- Death of 1 child (measles)
- U.S.-born child with congenital rubella

2003

 Delay of resettlement >6 m during outbreak control period 2006: Polio, Dadaab, Kenya (Somali refugees)

 Related outbreak control costs: \$309,283

2005 2006 2011

Dec 2012
Vaccine
Program
Starts

2005: Measles, Eastleigh, Kenya (Somali refugees)

- CDC recommended vaccination & waiting 1 incubation period before resettlement
- Recommendations not implemented due to cost concerns
- Results: Ill refugee arrives in U.S.; domestic outbreak response and surveillance

2011: Measles, Kuala Lumpur, Malaysia (Burmese refugees)

- Symptomatic in-flight; transmission to 2 other children on the plane
- Several epidemiologically linked cases, including a case in a CBP officer
- Extensive overseas & domestic outbreak control and vaccination efforts
- Related costs ~\$130,000

Cost Comparison: Vaccination Program

- Giving 10 doses of vaccines (2 doses of each of 5 childhood vaccines) overseas costs 76% less than giving the same vaccines in the US [\$93 vs \$388]
- Giving 10 doses of vaccines overseas represents a 16-25% reduction in getting a child <u>fully vaccinated</u> (35 doses of routine childhood vaccines as per ACIP) [\$1406 vs \$2020]
- Additional benefits of eliminating serious diseases in the refugees, preventing outbreaks and importation into the U.S.





Successful Overseas Interventions: Pre-departure Parasite Treatment Program

- Started in 1997 with parasite treatment for Barawan Somali refugees
- Now includes
 - albendazole and ivermectin for soil-transmitted helminths
 - praziquantel for schistosomiasis
 - artemetherlumefantrine for malaria





NVAC Global Immunizations Working Group Recommendation

Ensuring Immunization Coverage among U.S.-bound Refugees

The Assistant Secretary of Health (ASH) should endorse HHS coordination with other USG agencies to support efforts that provide routine overseas administration and documentation of vaccinations for all U.S.-bound refugees with vaccines that have been identified for pre- departure administration.





Refugee Vaccination Program: Overview

- Partnership between CDC and the Bureau of Population, Migration and Refugees (PRM), Department of State (DOS)
- Implemented by the International Organization for Migration (IOM)
- Start with 5 pilot host countries of asylum: Malaysia, Nepal,
 Thailand, Ethiopia and Kenya
- Plan to expand to 100% coverage for all refugees in U.S. Refugee Admissions Program (USRAP)





Refugee Vaccination Program: Overview

- Vaccinate U.S.-bound refugees according to the U.S. schedule as feasible
 - Subject-matter experts convened in 2010-2011 to develop schedule
 - Excludes a few currently unavailable or expensive vaccines (varicella, hepatitis A, Tdap, influenza, meningococcal)
- Procure vaccine through UNICEF or locally
- Assure proper cold chain, storage, handling and administration
- Provide documentation to U.S. domestic health care providers





Vaccine Schedule for Refugee Vaccination Program

Vaccine	Dose 1 (Initial Exam)	Dose 2 (4–8 weeks after the exam depending on vaccine and site logistics)		
DTP	5 yrs - < 7 yrs	N/A		
Hepatitis B	Birth - < 6 wks AND 5 yrs - adult	14 wks - adult		
Hib ^{1,2}	N/A (part of pentavalent)	14 wks - < 15 mos		
MMR	1 yr ³ - born in or after 1957	1 yr - born in or after 1957		
OPV (trivalent)	6 wks - < 11 yrs	14 wks - < 11 yrs		
PCV-13	6 wks - < 5 yrs ^{4,5}	14 wks - < 2 yrs ⁶		
Pentavalent ⁷ (DTP-HepB-Hib)	6 wks - < 5 yrs	N/A		
Rotavirus	6 wks- < 15 wks	14 wks - ≤ 8 mos		
Td ^{9,10}	7 yrs – adult	7 yrs – adult (see footnote for exclusions)		

¹also give 1 dose of Hib vaccine to <u>unimmunized</u> immunocompromised patients with functional asplenia aged ≥5 yrs, and to <u>unimmunized</u> HIV-infected patients aged 5-18 yrs²also give a dose to children now < 5 yrs old who were < 15 mos old when received previous dose

³start at age 6 mos during outbreaks

⁴also give one dose to immunocompromised refugees aged 5 yrs and older

⁵give one dose <u>only</u> of PCV-13 to all children <5 years who have received 4 doses of PCV-10 or PCV-7 series on vaccine history. Otherwise, vaccinate as per schedule in table for children with <4 doses of PCV-7 or PCV-10 vaccines on history

⁶also give additional dose to children now < 5 yrs old who were < 2 yrs old when received previous dose

⁷ if there is already a vaccination history of one or more component(s) of Pentavalent vaccine, separate vaccine components can be given instead.

⁸MAXIMUM age for dose 1 is 14 weeks 6 days. MAXIMUM age for dose 2 is 8 months.

give only ONE Td dose to children aged 7 and older who have any historical documentation of DTP or DTaP vaccine (regardless of when administered)

¹⁰do not give Td vaccine to children who have received DTP/DTaP within the last 12 months

Schedule: Catch-Up Considerations

Vaccine	Maximum number of doses (<u>including</u> doses on history)	Dose intervals recommended for USRAP	Minimum dose intervals (can be used if short of time)
DTP/DTaP	4 - If child has fully reliable vaccine records or IOM is certain the child has not received other DTP doses outside of what is documented on vaccine records. If there is any doubt about the vaccine record, or if the child does not have a vaccine record but lives in a setting where many refugee children have received DTP vaccines, only give DTP per schedule in table 1 and no further catch-up doses.	8 weeks EXCEPT dose 3 to dose 4 interval = 6 mos	 4 weeks for doses 1-2 and 2-3 6 months for dose 3-4 For <u>DTP only</u>—if a child already has 4 documented doses of DTP on history, <u>do not give</u> another dose, even if previous doses given below minimum age or interval²
Hepatitis B	3	8 weeks	 4 weeks for dose 1-2 8 weeks for dose 2-3 Dose 3 must be given at least 16 weeks after dose 1 AND minimum age for dose 3 is 24 weeks Do not count doses given below minimum age or interval as valid
НіЬ	4 (depending on current age and age at time of first dose; see ACIP and table 1); briefly: To get a 1st dose of Hib, child must be <5 yrs old OR have condition as specified in footnote 3 of table 1 To get a 2nd dose, child must have been <15 mos old during dose one To get a 3nd dose, child must have been <12 mos old during dose one AND <15 mos old during dose two To get a 4th dose, child must have been <12 mos old during doses one, two, and three	8 weeks	 4 weeks IF age <12 mos 8 weeks if age is 12 mos or older OR if age <12 mos but dose 1 was given at age ≥7 mos Do not count doses given below minimum age or interval as valid
MMR	2	8 weeks	4 weeks Do not count doses given below minimum age or interval as valid
OPV/IPV Trivalent ³	4	8 weeks EXCEPT dose 3 to dose 4 interval = 6 mos with minimum age 4 years for dose 4	 4 weeks for doses 1-2 and 2-3 6 mos for dose 3-4 AND minimum age for dose 4 must be 4 yrs Do not count doses given below minimum age or interval as valid
PCV-13	4 (depending on current age and age at time of first dose see ACIP)	8 weeks	 4 weeks IF age < 12 mos 8 weeks if age is 12 mos or older Do not count doses given below minimum age or interval as valid
Pentavalent	3	8 weeks	See individual vaccine components
Td	2 (see Table 1 footnotes 8 and 9)	8 weeks	4 weeks

Hepatitis B Pre-vaccination Testing

CDC, 2008

"All persons born in geographic regions with HBsAg prevalence of $\geq 2\%$... should be tested for chronic HBV infection. This includes immigrants, refugees, asylum seekers, and internationally adopted children born in these regions, regardless of vaccination status in their country of origin (123)... Because HBsAg prevalence can vary within these regions, additional knowledge about local HBsAg prevalence can be used to guide decision making regarding testing." (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm)

Rapid HBsAg

Vaccination of negatives; counseling of positives



Vaccination Program: Preparation

- USRAP Expanded Vaccination Program Manual
 - vaccine specific instructions,
 administration of vaccines, injection
 safety, etc.
- Contraindication/Precaution
 Checklist
- Vaccine Information Statements (VIS)
- Country-specific Standard
 Operating Procedures (SOPs)
- Adverse Effects Reporting Tool




Training Materials

Centers for Disease Control and Prevention and International Organization for Migration

USRAP Expanded Vaccination Program

Manual and Standard Operating Procedures


Vaccine Information Statements (VIS) and Contraindications Checklist



Adverse Events Monitoring

To date, 21 patients with 24 AEs reported from 5 sites

ANNEX 7 (AEFI Notification Form) Form to be sent to CDC at vaccinepilot@cdc.gov as soon as possible after occurrence of adverse event. IOM facility\Country Alien ID Sex □M □ F Case number Family name First name Camp or city Block or Location Date of Immunization Date of Birth/Age Date of AEFI onset Interval to symptoms Days Hours Date of notification Date of Investigation Type of AEFI Systemic CNS Injection site abscess Anaphylaxis Acute flaccid paralysis Severe Local Reaction Toxic Shock Encephalopathy Other, specify (see attached table, or other) Encephalitis\Meningitis Seizure (within 3 days) All vaccines given on date of immunization Administered by: Manufacturer Vaccine Expiry date Lot No. Dose # Relevant past medical history (e.g. underlying conditions, birth defect, allergies, similar reactions in past) Outcome (check all that apply) Treatment or clinic visit required ☐ No ☐ Yes, specify Hospitalized ☐ No ☐ Yes, specify days Permanent disability □ No □ Yes, specify Life-threatening illness □ No □ Yes, specify □ No □ Yes Recovered ☐ No ☐ Yes, specify Specimen Collection and dispatch (if any) Specimen type Date collected Dispatched to Date of dispatch Initial report (within 48 hours) Investigation (within 2 weeks if applicable)* * Full investigation to be conducted within 2 weeks in case of severe or clustered events. IOM Reporter IOM Investigator



Vaccination Program: Preparation

- Cold chain maintenance & CDC Storage and Handling Toolkit
- Emergency Power Supply and Retrieval Plan
- Medical Procurement Guidance
- On-site Training



Cold Chain

Visible thermometer

Water bottles for insulation.

No food in fridge.



SMS system for remote monitoring

Sheets for BID temperature monitoring


Plugs labeled 'do not disconnect'

Cold-Chain Safeguards










Supply Stocks and Logbooks







Documentation: New DS-3025 Form

Photo	(2) , v	ACCIN	То	DOCU Be Complete For US Vac	ed by Pane ocination Re	TATION I Physician O equirements	nly	RKSHEE	EXPIR	io. 1405-0113 ATION DATE: 09/30/2017 ATED BURDEN: 30 minutes Page 2 of 2)
	Name (Last, First, MI) GIVE COPY TO APPLIC Birth Date (mm-								Blanket Waiver(s) To Be Requested If Vaccination Not	
	Passport Nu	mber			Alie	n (Case) Nur	Number			Medically Appropriate.
Vaccine History	Vaccine History Transferred From a Written Record Given By Refugee Viet Characterisally from Juff to Birth Resulted date as your did your					Designated gees Only: Immunity nal Vaccine n by IOM*		Indicate reason below. Mark all that apply (see legend):		
Vaccine		Date	Date	Date	Date	Date	Date	Date	Date	A, B, C, D, F, H
Diphtheria, tetanus, DT, DTP, DTaF Td										
Polio OPV IPV										
Measles, mumps, n	ubella									
Mumps Rubella										
Rotavirus RotaTeq (RV5) Rotarix (RV1)										
Hib Hepatitis A										
Hepatitis B								_		
Meningococcal MCV4 Other MCV con	njugate									
Varicella Vaccine Varicella Histor	у									
PCV 10 PCV 13					 	<u></u>			ļ	
PPSV 23 Influenza										
Other										
2. Summary for US vaccination requirements US vaccination requirements NOT Complete COMPLETE Requesting a Blanket Waiver Requesting Individual Waiver base or moral convictions Requesting Adoptee Exemption Applicant refuses vaccinations				r based on religious tion						
-	3. Panel Physician Name (printed) Panel Physician signature Date (mm-dd-yyyy) Lattest I performed this examination and have an agreement with the Department of State or									
supervised completion of this form. I am the same Panel Physician that signs the DS 2054. * Only for designated refugees in special IOM Blanket waiver legend: A Not age appropriate B insufficient time interval to complete series										

Electronic Data Transmission





Overseas vaccination data in IOM's MiMOSA -> CDC's Electronic Disease Notification (EDN) System -> U.S. state refugee health programs/clinics

Example: Thailand Vaccine Administration



Nurse draws up doses on-site




If prefilling done, is very limited; clearly labeled



Individual tray with doses for one patient



Second nurse administers vaccine; patient is seated



IOM-given vaccines documented, attached to child's camp record

Implementation Challenges

- Assessing validity of camp-based vaccination from health partners
- Logistics of 2nd dose
- No live vaccines administered within 30 days of other live vaccines
- Outbreaks & changes to vaccine schedule
- Adverse events monitoring in nonprimary care setting
- Staffing and training
- Internet access for data entry/documentation





Implementation Challenges: Procurement and Importation

- Vaccine procurement
 - Small amounts challenging to procure from UNICEF
 - Each country with different availability/formulation



- Importation of vaccines
 - Country-specific requirements
- Pharmacy distribution hub established in Nairobi

Implementation Challenges: Cold Chain



Implementation Challenges: Access for 2nd Doses

Scheduling of 2nd doses — careful planning required!





Photo courtesy of Luis Ortega, CDC-TUC

Photo courtesy of Warren Dalal, IRMHB

Expanded Vaccination Program for U.S.-bound Refugees, 2015 Nepal 4,510 Refugees Coverage: 4,510 (100%)* Ethiopia 3,281 Refugees Coverage: 3,217 (98%)* Uganda Thailand 2,570 Refugees 4,251 Refugees Coverage: 2,545 (99%)* Coverage: 4,251 (100%)* Malaysia Kenya 9,475 Refugees 5,051 Refugees Coverage: 9,427 (99%) Coverage: 4,994 (99%)* Vaccinations Given Children Rwanda - Diptheria, Tetanus, Pertussis Coverage data not yet available Hepatitis B since the program started mid-Nov 2015 - Haemophilus influenzae, b - Measles, mumps, rubella - Rotavirus - Polio - Pneumococcal (pending) Implementation Dates Adults - Dec 2012: Nepal, Thailand He patitis B Sep 2013: Kenya, *Coverage rates depict eligible refugees who have had ≥ 1 dose of tetanus-diphtheria-containing vaccine - Measles, mumps, rubella Malaysia in CY 2015. This includes people with historical (pre-IOM) doses that were counted towards the - Tetanus, diptheria - Nov 2013: Ethiopia schedule. - Aug 2014: Uganda

Vaccination, CY 2013-2015

- > 100,000 refugees vaccinated
- ~700,000 doses of vaccine

	2013	2014	2015	Total
# refugees vaccinated	29,464	42,058	29,145	100,667
# vaccine doses	222,986	255,613	219,657	698,256





Monitoring & Evaluation

- Site visits
- Documentation review
- Outbreak tracking
- Coverage reports

	Pilot Vaccination Site Assessment Checklist for IOM/CDC Supportive Site Visits						
Site:	Site: Country:						
Chec	Checklist Completed By:						
Logisti	cs, Documentation and Log books	Comments					
	Site has the manual titled, "USRAP Expanded Vaccination Program"?						
	Site has the country specific operational plan for the vaccination program.						
	Site has a central log book for all vaccines that is appropriately filled out and also shows the distribution of vaccines?						
	Has documentation of the number of vaccines used and wastage rates for the site.						
	Reviews vaccination records to ensure they are acceptable documentation; rejects records of questionable authenticity						
	Has enough supplies of AD syringes, vaccine and diluents, mixing syringe, safety boxes adequate as per the projected work plan?						
	Exhibits knowledge of how to complete "Vaccination Documentation Worksheet" (DS-3025) and immunization section of DS-2053						
Knowl	edge of Technical Instructions						
	Knows the proposed vaccine schedule for the pilot program or has it easily accessible for quick reference						
	Knows general contraindications and/or precautions for vaccinations being used or has a list of them for quick and easy reference.						
	Understands how to fill out the contraindication/precaution checklist and can demonstrate how to fill it out						
	Can identify common Adverse Events Following Immunizations (AEFI)						
Cold C	hain Maintenance and Supply						
	Has a copy of CDCs Vaccine and Storage Handling Toolkit 2012 available						
	Uses appropriate freezer and refrigerator, or refrigerator with freezer unit						
П	Keens a calibrated thermometer in refrigerator and freezer to monitor temperatures						

Domestic Evaluation of the Overseas Vaccination Program

- Objective
 - Was overseas vaccination information received? How?
 - Over-vaccination? Under-vaccination?
- Methods
 - Collaboration with 17 state refugee health coordinators & cooperative agreement partners
 - Review sample of 1,500 refugee records that resettled from 5 countries to 17 domestic states





Summary: MMR Results

<u>Objective</u>	<u>Results</u>	<u>n</u>	<u>%</u>
Overseas Documentation	State received overseas documentation	972	87
Domestic	Appropriately vaccinated	829	85
Vaccinations	Under-vaccinated	37	4
	Over-vaccinated	94	10
	Inappropriately vaccinated	12	1
	n=11→born before 1957 n=1→medical contraindication		





Registry Project

- Electronic transfer of refugee overseas and domestic vaccination information from refugee health screening clinic databases into state immunization registries
- Adding unique refugee identifier to the state registry
- Assessment of coverage and completion rates over time
- Pilot in 5 states: Colorado, Kentucky, Massachusetts, Minnesota, New York





Vaccination Program: Summary

- First implemented in December 2012
- Now fully operational in 8 countries
 - Covering ~50-60% of U.S.-bound refugees
 - Implemented in Thailand, Malaysia, Nepal, Thailand, Ethiopia, Kenya, Rwanda, Uganda
 - Other countries in process
- In 2013-2015, >100,000 refugee beneficiaries to date, ~700,000 doses of vaccine





Vaccination Program: Next Steps

Overseas

- Update schedule periodically based on vaccine availability and U.S. schedule/ACIP changes
- Monitor/respond to VPD outbreaks
- Identify/address cold chain issues
- Enhance staff training and health education for refugees
- Improve adverse events reporting

Domestic

- Promote awareness of program
- Improve U.S. clinician access to vaccine records via EDN
- Establish linkages with state registries
- Expand to other countries overseas





Program Expansion

Tier	Countries	Status	Comments
Tier 1	Ethiopia, Kenya, Uganda, Malaysia, Nepal, Thailand	Complete, in M&E phase	Large IOM programs
Tier 2	Rwanda, Burundi, Tanzania, Chad, Zambia, Jordan, Iraq, Slovakia, Romania, Former Soviet Union, Indonesia, others	Initial assessment and implementation phase in FY 2016	Smaller IOM programs, panel physicians may be subcontracted by IOM
Tier 3	Turkey, Egypt, Lebanon, Austria, Malta, other countries	In discussion	non-IOM panel physicians

Thank You! Questions?





